Pivotal Therapeutics Inc. Announces First Prescription Sales in the United States
5/22/2012 10:09:49 AM
WOODBRIDGE, Ontario--(BUSINESS WIRE)--Pivotal Therapeutics Inc. (CNSX: PVO; OTCQX: PVTTF), a specialty pharmaceutical company with a focus on cardiovascular health, is pleased to announce that prescription sales have begun in the United States for its lead therapeutic VASCAZEN™. A prescription-only medical food for the aid in the dietary management of Omega-3 deficient cardiovascular disease patients, VASCAZEN™ is now available through prescription in a vast majority of pharmacies throughout the US and is receiving partial reimbursement from a growing number of the nations largest private insurers.